How Much Does Anktiva Cost?

Published on November 27, 2025 | Prices Last Reviewed for Freshness: February 2026
Written by Alec Pow - Economic & Pricing Investigator | Medical Review by Sarah Nguyen, MD

Educational content; not medical advice. Prices are typical estimates and may exclude insurance benefits; confirm with a licensed clinician and your insurer.

Anktiva, also known as nogapendekin alfa inbakicept pmln, was approved in 2024 for BCG unresponsive non muscle invasive bladder cancer and it sits inside one of the most expensive corners of modern oncology care, as outlined by Vax Before Travel.

In practical terms, Anktiva is an intravesical interleukin 15 based immunotherapy given together with BCG for adults with BCG unresponsive non muscle invasive bladder cancer, particularly those with carcinoma in situ. It is manufactured by ImmunityBio and delivered directly into the bladder during outpatient visits, which means the drug appears on hospital or clinic bills rather than at a retail pharmacy.

List prices tell only part of the story. The wholesale acquisition cost for a single 400 microgram dose of Anktiva is about $35,800, and treatment is delivered as a series of instillations alongside BCG over many months, so the line items for drug alone add up very quickly before facility or physician fees are included, according to the Anktiva how to order page.

Bladder cancer itself is already expensive to manage. Estimates compiled from U S claims data suggest average treatment spending per patient ranges from about $19,521 for early stage disease up to around $169,533 for metastatic cases, even before layering in newer biologic drugs, according to a bladder cancer cost overview.

People searching for “anktiva cost” are usually trying to map a very specific scenario, such as the price per instillation, the total value of an induction and maintenance plan, or the out of pocket bill after insurance, and because oncology billing involves list prices, negotiated discounts, assistance programs and multiple providers, a structured look at each component of spending helps bring that picture into focus, as summarized in The Medical Letter overview.

Anktiva cost snapshot (2025-2026)

• List price per dose: about $35,800 per 400 microgram vial in the United States.
• Typical dosing: 6 week induction with BCG, optional second induction, plus maintenance instillations over roughly three years (often up to ~27 doses in total).
• Theoretical full course drug bill: can approach $1.1 million at list level if all planned doses are given.
• Real world patient cost: often capped at a few hundred dollars for drug with commercial copay support, or at the annual out of pocket maximum for many Medicare Advantage members.
• Main cost drivers: number of doses actually received, insurance design, where treatment is delivered, and eligibility for copay or patient assistance programs.

How Much Does Anktiva Cost?

At the list level, Anktiva is priced at a wholesale acquisition cost of about $35,800 per dose in the United States, a figure confirmed both by the manufacturer’s ordering guide and independent drug pricing files from state transparency reports and pharmacy benefit managers. This catalog price is the starting point for most payer contracts and does not reflect confidential rebates or discounts negotiated by insurers and large health systems, as detailed in the official ordering PDF.

The recommended Anktiva schedule for BCG unresponsive non muscle invasive bladder cancer includes a six week induction course with BCG, an optional second six week induction course if a complete response is not reached at three months, and then three weekly maintenance instillations at months 4, 7, 10, 13 and 19, with additional maintenance possible later for sustained responders, so a full sequence can involve up to 27 or more doses over about three years. At list price, that many instillations would translate to a theoretical drug invoice that climbs toward or beyond $1.1 million, a figure echoed in a Prime Therapeutics drug update that models revenue for a full induction and maintenance course.

Also read our articles on the cost of Leucovorin, Revlimid, or predictive genetic testing.

Real world treatment usually lands somewhere below that ceiling because not every patient receives a second induction course and some discontinue earlier because of disease progression, toxicity or personal choice, yet even simplified scenarios remain large. If a patient receives nine doses in a first year, which can be a realistic count when induction and early maintenance are combined, the Anktiva drug component alone would carry a nominal list value of roughly $322,200 before any payer discounts, facility fees, or BCG charges, a level highlighted in a Seeking Alpha pricing analysis.

Clinical trial data for BCG unresponsive carcinoma in situ reported complete response rates in roughly seven out of ten patients, which means that in simple models the first year list price per responding patient can exceed $450,000 when induction and early maintenance doses are counted. In economic discussions, that figure is often weighed against the direct medical cost of radical cystectomy, which many studies place in the $30,000–$40,000 band for surgery and immediate postoperative care, even though surgery and bladder sparing immunotherapy have very different quality of life profiles over time.

Those figures sit on top of the existing cost of BCG therapy and cystoscopy based surveillance, which themselves are not trivial; a Florida urology clinic that publishes patient facing price ranges lists initial hospital charges for tumor resection in the $5,000–$7,000 band and BCG therapy in the low five figure range for a full induction sequence, even before physician fees and imaging are counted, in its Florida Urology cost breakdown.

Real life cost examples

Sticker shock comes quickly. Yet the gap between list price and what households actually pay can be wide because insurance coverage, copay programs and assistance funds reshape the bill, as described in the ImmunityBio CARE guide.

Commercially insured patient example

Consider a commercially insured patient in Chicago whose oncologist prescribes six Anktiva doses for induction and three early maintenance instillations, for nine total treatments in the first year. At WAC, the drug line would show about $322,200, yet the manufacturer sponsored copay program allows eligible commercially insured patients to pay as little as $25 per dose, with a maximum annual benefit of $25,000, so this patient’s out of pocket share for the drug itself might be around $225 if the health plan covers the rest. The larger exposure would come from visit copays and coinsurance on facility services, which easily add several thousand dollars during repeated cystoscopy and instillation visits, according to the Accredo enrollment form.

Medicare Advantage patient example

A Medicare beneficiary in Phoenix with a Medicare Advantage plan faces a different structure. Outpatient cancer drugs that are clinician administered are usually billed under Part B and then processed by the plan, so the member might see 20 percent coinsurance on the drug and facility line items until the plan’s annual out of pocket maximum is reached. In a scenario where billed Anktiva, BCG and outpatient fees in the first year total $350,000, an out of pocket maximum in the $7,000–$9,000 band would cap the member’s share, but that limit may still represent a substantial share of household income for a retiree on a fixed budget, based on Medicare outpatient rules.

Uninsured or underinsured patient example

Uninsured or underinsured patients can sometimes qualify for the patient assistance program highlighted in the ImmunityBio CARE materials, which provides free product for those who meet income and coverage criteria; even then, hospital or infusion center charges, professional fees, imaging, and travel expenses remain, so a household might still face out of pocket spending in the low to mid five figure range over several years of surveillance and treatment, as noted in Anktiva support and resources.

Cost breakdown

Anktiva cost is best understood as a package of parallel expenses. The headline item is the drug itself at roughly $35,800 per vial, multiplied by however many vials are used for induction and maintenance in a particular case, but hospital and clinic charges, BCG supply cost, physician evaluation visits, cystoscopy procedures, cytology tests, imaging and pharmacy markups all contribute meaningful slices of the total, as outlined in a Medical Letter dosing and cost review.

Key cost components typically include:

• Drug costs: Anktiva itself plus BCG and supportive medications.
• Facility fees: Outpatient hospital or ambulatory surgery center charges for intravesical instillation and related procedures.
• Professional fees: Urology and oncology visits, surgical fees, anesthesia when procedures such as tumor resection are performed.
• Surveillance and diagnostics: Cystoscopy, cytology, pathology, CT or MRI imaging and routine lab work.
• Pharmacy and administration: Nursing time, pharmacy preparation fees and supplies used during each instillation.

Facility fees can be substantial. The Florida Urology example points to outpatient charges in the low thousands for procedures like transurethral resection and intravesical instillation, and broader analyses of bladder cancer care have found that repeated cystoscopies, imaging studies and pathology reviews create a persistent stream of charges over many years, especially in non muscle invasive disease that requires long term surveillance, as shown in a clinic pricing example from Florida Urology.

Drug administration adds its own line items, such as nursing time, pharmacy preparation fees and supplies used during each intravesical instillation, plus any premedications, antibiotics or pain management prescriptions given around treatment days; these often show up as smaller one to three figure amounts on statements, yet repeated many times they easily sum to several thousand dollars over the full window of therapy. Economic burden studies cite per patient annual spending in bladder cancer that often crosses $50,000 in older adults with high grade disease, even before new immunotherapies are adopted at scale, in an economic burden study.

Hidden costs are easy to overlook. Pre treatment lab panels and urine cultures can add $300–$1,000 per cycle, CT scans or MRIs for staging and response assessment often come with four figure price tags, and prescriptions for anti nausea drugs, bladder protectants or antibiotics can mean another $50–$300 every few visits, so even if a copay program zeros out the Anktiva invoice, a family still needs to plan for recurring ancillary charges that sit around the therapy, as discussed in a GU Oncology Now cost review.

Insurance coverage

In the United States, Anktiva is billed as a clinician administered oncology drug under the permanent HCPCS J code J9028, usually under the medical benefit (Medicare Part B or the medical side of a commercial plan) rather than the pharmacy benefit. That means Anktiva generally appears on hospital or clinic bills as a Part B drug charge, not at the retail pharmacy counter.

On an explanation of benefits (EOB), patients typically see separate lines for:

• The Anktiva drug itself (J9028), often grouped with other Part B drugs.
• Facility or outpatient hospital charges for the visit and instillation.
• Physician professional fees for evaluation and management, cystoscopy and procedures.
• Lab and imaging services billed by separate providers.

Commercial plans and Medicare Advantage policies apply their own coinsurance rules to each of these categories until the member reaches a deductible or annual out of pocket maximum. Because the drug line is so large at list price, even a small coinsurance percentage can quickly push a patient to their yearly maximum liability, after which covered services are usually paid at one hundred percent for the rest of the plan year. Understanding which benefit applies, how J9028 is processed and what the plan’s caps look like can help households anticipate their real exposure before the first instillation is scheduled.

Factors that influence costs

Several structural forces help explain why Anktiva pricing looks the way it does. Manufacturing a recombinant interleukin based biologic requires complex cell culture facilities, quality control systems and cold chain logistics, while the company also seeks to recoup years of clinical trial spending, regulatory work and earlier research on the IL 15 platform, so fixed costs per patient are high compared with older generic drugs in urology.

Market position also matters. Anktiva has Breakthrough Therapy and RMAT designations and fills a niche in BCG unresponsive non muscle invasive bladder cancer where options have historically been limited, so pricing strategy reflects both clinical value arguments and the absence of direct generic competition, while payers weigh these claims against less expensive but more invasive options such as cystectomy, according to an ImmunityBio investor update.

On the payer side, the assignment of permanent HCPCS J code J9028 in January 2025 gives Medicare and commercial insurers a clearer framework for reimbursement, and press releases from ImmunityBio highlight a sharp increase in unit volume after the code became permanent, which suggests that coverage decisions and contract negotiations are expanding access even while list price remains high, a point also noted in a Prime Therapeutics J code note. At the individual level, plan design, network status of the treating center, and whether a patient qualifies for copay or free drug programs all play a major role in the final out of pocket figure.

Alternative therapies

People researching Anktiva cost often want a sense of how it fits into the wider bladder cancer treatment market. In the same BCG unresponsive non muscle invasive space, alternatives like Adstiladrin, a gene therapy, and systemic checkpoint inhibitors such as pembrolizumab provide different combinations of efficacy, administration route and price, and in many cases they compete directly for the same high risk patients, as reviewed in a Urology Times economics review.

A 2024 financial analysis cited by Urology Times puts pembrolizumab spending for bladder cancer in the neighborhood of $150,000 per year, depending on dose and schedule, while Adstiladrin is described with a per treatment figure around $70,000, often delivered in four instillations over a year, implying an annual drug bill near $280,000. An investing research note on ImmunityBio’s pricing strategy contrasts that range with Anktiva’s projected full course revenue of about $1.1 million, highlighting just how far the new drug pushes nominal spending in comparison, based on Urology Times cost ranges.

The table below summarizes approximate price levels for key therapies competing in the high risk non muscle invasive bladder cancer space, using list level or modeled figures from payer and investor reports such as a pricing comparison source rather than the net amounts paid after discounts or rebates.

Ways to spend less

Households rarely pay the sticker price shown in drug compendia, and Anktiva is no exception. The manufacturer’s ImmunityBio CARE program bundles benefits verification, prior authorization support and two core financial tools, a copay assistance program for eligible commercially insured patients and a patient assistance program that can provide free drug to qualifying uninsured or underinsured people, as described in the CARE program guide.

For commercially insured patients, the copay program described in Accredo and ImmunityBio documents can reduce out of pocket drug coinsurance to as little as $25 per dose with an annual maximum benefit of $25,000, as long as the plan itself covers Anktiva for the FDA approved indication; that structure means the household pays a predictable small amount at each treatment visit while the program covers the rest of the patient’s share up to the benefit cap. Separate patient assistance criteria, based on income thresholds and insurance status, allow some individuals with no coverage or inadequate coverage to receive Anktiva free of charge, even though they remain responsible for hospital or clinic fees, according to Accredo copay terms.

Beyond manufacturer support, choosing an in network facility, consolidating lab work and imaging to minimize repeated copays, and asking the oncology clinic’s financial counseling team to run estimates before scheduling induction can uncover ways to spread payments or qualify for hospital based charity care, especially in systems that participate in 340B pricing and may have more flexibility on margins. Some families also compare travel and lodging support from national cancer nonprofits when the only available Anktiva center is in another city, since help with gas, hotels and parking can change the effective cost of treatment, including the American Cancer Society’s support programs.

Questions to ask your care team about Anktiva cost

• “Will Anktiva be billed under my medical benefit (Part B) or pharmacy benefit, and what coinsurance applies?”
• “What is my most likely annual out of pocket maximum if I start this treatment?”
• “Can your financial counselor help me apply for the copay or patient assistance programs before we begin?”
• “How will my costs change if we stop early because the treatment is not working or side effects are too high?”
• “Are all the labs, imaging and cystoscopies being done in in network facilities to keep my share lower?”

Answers to Common Questions

How much does Anktiva cost per dose at list price?

Anktiva’s wholesale acquisition cost is about $35,800 per 400 microgram vial in the United States, according to the official ordering guide and drug pricing transparency reports; insurers often pay less after negotiated rebates, but that figure is the anchor used in many cost models.

What is the estimated total cost of a full Anktiva course?

Investor research that multiplies recommended induction and maintenance doses by the list price suggests that a complete long term course can generate drug invoices around $1.1 million, although real world totals may be lower because some patients do not complete the entire schedule or stop after one induction.

How much do patients usually pay out of pocket for Anktiva?

Out of pocket exposure varies, but documentation from the ImmunityBio CARE and Accredo programs shows that eligible commercially insured patients can see their drug copay reduced to as little as $25 per dose up to a yearly cap, while many Medicare Advantage and Medicare supplement enrollees hit their plan’s annual out of pocket maximum and then see covered oncology services paid at one hundred percent for the rest of the year.

Are there programs that can make Anktiva free for eligible patients?

Yes, the ImmunityBio CARE materials describe a patient assistance program that can provide Anktiva at no charge for uninsured or underinsured patients who meet income and clinical criteria, while copay programs and foundation grants can reduce or cover drug copays for some insured patients, although facility and physician charges still apply.

How does Anktiva price compare with Adstiladrin or pembrolizumab?

Published estimates place Adstiladrin course costs in the roughly $240,000–$280,000 band and pembrolizumab bladder cancer regimens near $150,000 per year at list level, which keeps both therapies below Anktiva’s modeled $1.1 million full course total, even though the net paid amounts after rebates can narrow those differences, as reported in Urology Times comparisons.